[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:high-grade-b-cell-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"High Grade B-Cell Lymphoma","CD19 Gene",9,[8,16,23,29,36,41,47,54,60],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07042438","Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells",[12],"Phase 2","RECRUITING","2026-08-26T02:15:11.740957Z","2026-05-05T02:35:31.730111Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[20],"Phase 1","2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[12],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT07188558","A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy",[33],"Phase 3","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.052132Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":27,"content_modified":40},"NCT05077527","Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma",[20],"2026-05-05T02:43:29.044473Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[51],"Phase 1\u002FPhase 2","2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05672251","Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.249867Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[20],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z"]